Literature DB >> 19383911

Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

Kuan-Ting Kuo1, Bin Guan, Yuanjian Feng, Tsui-Lien Mao, Xu Chen, Natini Jinawath, Yue Wang, Robert J Kurman, Ie-Ming Shih, Tian-Li Wang.   

Abstract

Ovarian serous carcinoma, the most common and lethal type of ovarian cancer, is thought to develop from two distinct molecular pathways. High-grade (HG) serous carcinomas contain frequent TP53 mutations, whereas low-grade (LG) carcinomas arise from serous borderline tumors (SBT) and harbor mutations in KRAS/BRAF/ERBB2 pathway. However, the molecular alterations involved in the progression from SBT to LG carcinoma remain unknown. In addition, the extent of deletion of tumor suppressors in ovarian serous carcinomas has not been well studied. To further address these two issues, we assessed DNA copy number changes among affinity-purified tumor cells from 37 ovarian serous neoplasms including SBT, LG, and HG tumors using high-density 250K single nucleotide polymorphism arrays. Chromosomal instability index as measured by changes in DNA copy number was significantly higher in HG than in LG serous carcinomas. Hemizygous ch1p36 deletion was common in LG serous carcinomas but was rarely seen in SBT. This region contains several candidate tumor suppressors including miR-34a. In contrast, in HG serous carcinomas, significant numbers of amplifications and deletions, including homozygous deletions, were identified. Among homozygous deletions, loci containing Rb1, CDKN2A/B, CSMD1, and DOCK4 were most common, being present in 10.6%, 6.4%, 6.4%, and 4.3%, respectively, in independent 47 affinity-purified HG serous carcinomas. Except for the CDKN2A/B region, these homozygous deletions were not present in either SBT or LG tumors. Our study provides a genome-wide homozygous deletion profile in HG serous carcinomas, which can serve as a molecular foundation to study tumor suppressors in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383911      PMCID: PMC2782554          DOI: 10.1158/0008-5472.CAN-08-3913

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Transcript map of the 8p23 putative tumor suppressor region.

Authors:  P C Sun; R Uppaluri; A P Schmidt; M E Pashia; E C Quant; J B Sunwoo; S M Gollin; S B Scholnick
Journal:  Genomics       Date:  2001-07       Impact factor: 5.736

2.  DOCK4, a GTPase activator, is disrupted during tumorigenesis.

Authors:  Vijay Yajnik; Charles Paulding; Raffaella Sordella; Andrea I McClatchey; Mako Saito; Doke C R Wahrer; Paul Reynolds; Daphne W Bell; Robert Lake; Sander van den Heuvel; Jeff Settleman; Daniel A Haber
Journal:  Cell       Date:  2003-03-07       Impact factor: 41.582

3.  Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas.

Authors:  Rong Wu; Lin Lin; David G Beer; Lora H Ellenson; Barbara J Lamb; Jean-Marie Rouillard; Rork Kuick; Samir Hanash; Donald R Schwartz; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Diverse tumorigenic pathways in ovarian serous carcinoma.

Authors:  Gad Singer; Robert J Kurman; Hsueh-Wei Chang; Sarah K R Cho; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

5.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

Authors:  Gad Singer; Robert Oldt; Yoram Cohen; Brant G Wang; David Sidransky; Robert J Kurman; Ie-Ming Shih
Journal:  J Natl Cancer Inst       Date:  2003-03-19       Impact factor: 13.506

6.  Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study.

Authors:  John Farley; Leia M Smith; Kathleen M Darcy; Eugene Sobel; Dennis O'Connor; Benita Henderson; Larry E Morrison; Michael J Birrer
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

7.  Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.

Authors:  Andrea Flesken-Nikitin; Kyung-Chul Choi; Jessica P Eng; Elena N Shmidt; Alexander Yu Nikitin
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

8.  Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.

Authors:  Peter Schraml; Georg Schwerdtfeger; Felix Burkhalter; Anna Raggi; Dietmar Schmidt; Teresa Ruffalo; Walter King; Kim Wilber; Michael J Mihatsch; Holger Moch
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.

Authors:  Nathalie L G Sieben; Patricia Macropoulos; Guido M J M Roemen; Sandra M Kolkman-Uljee; Gert Jan Fleuren; Rifat Houmadi; Tim Diss; Bretta Warren; Mudher Al Adnani; Anton P M De Goeij; Thomas Krausz; Adrienne M Flanagan
Journal:  J Pathol       Date:  2004-03       Impact factor: 7.996

Review 10.  Chromosome aberrations in solid tumors.

Authors:  Donna G Albertson; Colin Collins; Frank McCormick; Joe W Gray
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

View more
  86 in total

1.  Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.

Authors:  Elisabetta Kuhn; Alan Meeker; Tian-Li Wang; Ann Smith Sehdev; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

2.  Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.

Authors:  Elisabetta Kuhn; Alan K Meeker; Kala Visvanathan; Amy L Gross; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

3.  Whole exome sequence analysis of serous borderline tumors of the ovary.

Authors:  Jeff Boyd; Biao Luo; Suraj Peri; Beth Wirchansky; Lucinda Hughes; Caitlin Forsythe; Hong Wu
Journal:  Gynecol Oncol       Date:  2013-06-14       Impact factor: 5.482

Review 4.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

5.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

Review 6.  Latest research and treatment of advanced-stage epithelial ovarian cancer.

Authors:  Robert L Coleman; Bradley J Monk; Anil K Sood; Thomas J Herzog
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

7.  Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

Authors:  Marta Llauradó Fernández; Gabriel E DiMattia; Amy Dawson; Sylvia Bamford; Shawn Anderson; Bryan T Hennessy; Michael S Anglesio; Trevor G Shepherd; Clara Salamanca; Josh Hoenisch; Anna Tinker; David G Huntsman; Mark S Carey
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

8.  DNA copy number profiling in microsatellite-stable and microsatellite-unstable hereditary non-polyposis colorectal cancers by targeted CNV array.

Authors:  Weixiang Chen; Jun Ding; Long Jiang; Zebing Liu; Xiaoyan Zhou; Daren Shi
Journal:  Funct Integr Genomics       Date:  2016-11-28       Impact factor: 3.410

9.  KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Authors:  Yvonne T Tsang; Michael T Deavers; Charlotte C Sun; Suet-Yan Kwan; Eric Kuo; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

10.  Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository.

Authors:  Rayna K Matsuno; Mark E Sherman; Kala Visvanathan; Marc T Goodman; Brenda Y Hernandez; Charles F Lynch; Olga B Ioffe; David Horio; Charles Platz; Sean F Altekruse; Ruth M Pfeiffer; William F Anderson
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.